-
One picture to understand 13 PD-1/PD-L1 drugs approved in China
Time of Update: 2022-05-20
>released in 2021, is liked by many readers. After 4 months, a remake version will be released. The update date is as of April 28, 2022. Follow China's PD
-
The next round of competition for domestic PD-1 is shifting to overseas markets
Time of Update: 2022-05-20
On April 13, 2022, Junshi Bio announced that toripalimab, an anti-PD-1 monoclonal antibody independently developed by the company for the treatment of small cell lung cancer (SCLC), has been approved by the U.
-
First completed the administration of the first subject of the Phase I clinical trial for the oral preparation of GLP-1 polypeptide XW004
Time of Update: 2022-05-20
Pan Hai, founder and CEO of Xianweida, said, "The initiation of this Phase 1 MAD clinical study is the first step in developing XW004 as a safe and effective therapy for patients with metabolic diseases .
-
Pemetrexed: Folic acid and VB12 applied 1 week in advance or at the same time?
Time of Update: 2022-05-20
Timing offolic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
-
Vietnam's monthly export of aquatic products reaches 1 billion US dollars
Time of Update: 2022-05-19
Vietnam Herald website reported on April 27, 2022, according to data from Vietnam Association of Aquatic Products
-
Uric acid less than 1 μmol/L?
Time of Update: 2022-05-19
>foreword>forewordUric acid is the final product of purine metabolism, produced by xanthine
-
"Cold" tumor becomes "hot" Oncolytic virus/CAR-T combination therapy Phase 1 clinical trial is about to start
Time of Update: 2022-05-19
April 18, 2022, from https://ir . mustangbio. com/news-events/press-releases/detail/137/mustang-bio-announces-a-phase-1-clinical-trial-combining>
-
Diabetologia: Early and late histological confirmation of celiac disease in children with new-onset type 1 diabetes
Time of Update: 2022-05-19
>>Table 1 Adjusted outcome variables for participants with early versus delayed histological diagnosis of celiac disease (n = 411) at the last follow-up visit>>Figure 2 SDS
-
with pembrolizumab in patients with advanced melanoma resistant to PD-1 immunotherapy
Time of Update: 2022-05-18
This is a single-arm study (NCT04570332) of intratumoral BO-112 and intravenous pembrolizumab in patients with melanoma (skin, condyloma, or mucosa) receiving anti-PD1 therapy and confirmed progressive disease (PD) .
-
NICE recommends Koselugo for neurofibromatosis type 1
Time of Update: 2022-05-18
Therefore, this Phase II trial concluded that most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas experienced significant clinical benefit with Koselugo .
-
In 2022, the "close relatives" of Class 1 innovative drugs will accelerate the launch of the outbreak
Time of Update: 2022-05-17
From the perspective of new improved chemical drugs (excluding new indications) approved from 2020 to the present, there are a total of levoornidazole tablets from Shenghe Pharmaceuticals, olanzapine oral dissolving film from Hansoh, and montelukast from Qilu Pharmaceuticals.
-
Diabetologia: Characteristics of Type 1 Diabetes and Refractory Hypoglycemia in Adults
Time of Update: 2022-05-17
AHN, normalization of asymptomatic hypoglycemia; HAP, avoidance of hyperglycemia prioritized; HCM, minimized hypoglycemia problems;Figure 2 k-means cluster analysis of the HARPdoc cohort with two clusters .
-
Nippon Paint Ranked No. 1 in China's Brand Power Index
Time of Update: 2022-05-17
On April 20, Nippon Paint China announced that in the 2022 (12th) China Brand Value Index Brand Ranking and Analysis Report released by the brand rating authority Chnbrand, Nippon Paint Wall
-
The large variety of anti-gout was "cut in half", and 4 new drugs of class 1 of traditional Chinese medicine were strongly filled
Time of Update: 2022-05-17
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
-
Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use
Time of Update: 2022-05-17
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
-
Sino Coatings helps "Hualong No. 1" overseas project
Time of Update: 2022-05-17
1" environmentally friendly nuclear-grade paint developed by Xinhe New Materials broke the long-term monopoly of Chinese nuclear power coatings by foreign brands, and became the only nuclear-grade paint supplier participating in the construction of all "Hualong No.
-
Vietnam's jackfruit exports are blocked, and the price per kilogram falls below 1 yuan
Time of Update: 2022-05-16
According to Vietnamese media reports, the current price of jackfruit in Vietnam is only VND 5,000-8,000/kg, which is about RMB 1.
-
Nat Commun: Transient viral exposure drives humoral immune responses in HIV-1 post-treatment controllers
Time of Update: 2022-05-16
The results of the study were published in the journal Nature Communications on April 11, 2022, with the title "Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers" .
-
J Periodontal Res: Is the presence of herpes simplex virus type 1 (HSV-1) associated with the development of gingivitis and periodontitis?
Time of Update: 2022-05-16
A meta-analysis of observational studies published in J Periodontal Res aims to investigate the strength and prevalence of the association of herpes simplex virus type 1 (HSV-1) in subjects with plaque-induced gingivitis and periodontitis .
-
The latest paper by Zhu Di’s team at Fudan University: RORγt agonists enhance anti-PD-1 therapy
Time of Update: 2022-05-15
On April 23, 2022, Researcher Zhu Di of Fudan University published a paper titled "RORγt agonist enhances anti-PD-1 therapy by promoting monocyte" in the Journal of Experimental & Clinical Cancer Research (IF=11.
